Market Overview

UPDATE: Jefferies Raises PT to $25 on Insulet Following Eros FDA Approval

Related PODD
DexCom Collaborates With Insulet Corporation - Analyst Blog
Increased Earnings Estimates Seen for Insulet (PODD): Can It Move Higher? - Tale of the Tape

Jefferies reiterated its Buy rating on Insulet (NASDAQ: PODD) and increased its price target from $23 to $25.

Jefferies said, "Insulet announced approval of the Eros pod this morning, bringing a close an almost two year 510k approval process. Insulet estimates it will take 45-60 days to educate customers and scale up to a full launch, which puts the beginning of the transition from the legacy pod to Eros in March. The company has stockpiled approximately 6-7 weeks of inventory with the current pod to enable a quick transition to Eros manufacturing."

Insulet closed at $21.85 on Friday.

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (PODD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters